Acclinate Funding: How Much Did They Raise & Key Investors

How Much Did Acclinate Raise?
Funding & Key Investors

Acclinate, a Birmingham-based digital health innovator, has successfully secured a significant capital injection, bringing its total funding to $10.5M. This latest infusion of $3.5M marks a pivotal moment in the company's trajectory as it scales its operations to address systemic gaps in clinical research participation. By leveraging this strategic investment, the firm is well-positioned to accelerate its mission of fostering inclusive genomic research and clinical trial environments.

The company's growth narrative is defined by a clear progression from its initial Series A round to this recent debt financing, reflecting a maturing business model that is increasingly vital to the biopharmaceutical sector. As the industry faces mounting pressure to ensure diverse representation in medical studies, Acclinate has emerged as a critical partner for organizations seeking to bridge the gap between research and underrepresented populations.

What is Acclinate?

Acclinate

Business Services

Research & Development

Acclinate operates at the intersection of digital health and clinical research equity. The company provides a specialized platform designed to assist biopharmaceutical firms and contract research organizations in diversifying their participant pools. By focusing on education and engagement, Acclinate empowers diverse individuals to make informed decisions regarding their health and participation in clinical trials. This approach not only enhances the scientific validity of genomic research but also ensures that medical advancements are representative of the broader population, thereby addressing long-standing disparities in healthcare outcomes.

How much funding has Acclinate raised?

Acclinate has raised a total of $10.5M across 2 funding rounds:

2024

Series A

$7M

2026

Debt

$3.5M

Series A (2024): $7M with participation from Labcorp

Debt (2026): $3.5M, investors not publicly disclosed

Key Investors in Acclinate

Labcorp

Labcorp is a global leader in laboratory services, providing comprehensive diagnostic and biopharma laboratory solutions to support medical research and patient care.

Undisclosed Investor

Undisclosed investor participating in the funding round.

Undisclosed Investor

Undisclosed investor participating in the funding round.

What's next for Acclinate?

With the recent capital deployment, Acclinate is poised to expand its technological infrastructure and deepen its reach within the global biopharma ecosystem. The strategic focus will likely center on scaling its digital engagement tools to support larger, multi-site clinical trials that require high-fidelity data from diverse cohorts. As the company transitions into this next phase of growth, it will likely prioritize partnerships with major laboratory services providers and research institutions to solidify its market position. The integration of its proprietary engagement methodology into standard clinical trial workflows remains a key objective, ensuring that health equity becomes a foundational element of future medical innovation.

See full Acclinate company page

See More Financial Insights